Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (19)

« Back to Publications

MYB activity drives emergent enhancer activation and enhancer-promoter interactions in acute lymphoblastic leukemia.

Lau I-J. et al, (2026), Blood

Monoclonal light chain glycosylation is associated with evolution of incidental MGUS

Larham J. et al, (2025), BLOOD, 146, 2185 - 2186

TRANSCRIPTION ELONGATION AND ABERRANT ENHANCER ACTIVATION IN LEUKEMIA

Milne T. et al, (2025), EXPERIMENTAL HEMATOLOGY, 151

The Utility of Mass Spectrometry in Defining Minimal Residual Disease in Treated Multiple Myeloma Patients

Campbell L. et al, (2024), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 24, S144 - S145

Sustained MYB activity is necessary for oncogenic transcription in KMT2A-rearranged acute lymphoblastic leukemia through enhancer-promoter interactions and epigenetic modifications at enhancers

Lau I-J. et al, (2023), Blood, 142, 40 - 41

Chromatin accessibility governs the differential response of cancer and T cells to arginine starvation.

Crump NT. et al, (2021), Cell Rep, 35

H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells.

Godfrey L. et al, (2021), Leukemia, 35, 90 - 106

DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation.

Godfrey L. et al, (2019), Nat Commun, 10

PF153 MLL‐AF4 CAUSES ABERRANT UPREGULATION OF PROM1 (CD133) IN ACUTE LYMPHOBLASTIC LEUKEMIA BY CONTROLLING ENHANCER‐PROMOTER INTERACTIONS

Godfrey L. et al, (2019), HemaSphere, 3, 29 - 29

Next generation sequencing techniques reveal molecular mechanisms of MYB regulation and function in MLL-AF9 Leukemia

Lau I-J. et al, (2017), Haematologica, 102

Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.

Quek L. et al, (2016), J Exp Med, 213, 1513 - 1535

MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome.

Stavropoulou V. et al, (2016), Cancer Cell, 30, 43 - 58

Management and controversies of classical Hodgkin lymphoma in pregnancy.

Eyre TA. et al, (2015), Br J Haematol, 169, 613 - 630

Management and controversies of classical Hodgkin lymphoma in pregnancy

Eyre TA. et al, (2015), British Journal of Haematology, 169, 613 - 630

Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.

Lau I-J. et al, (2015), Ann Hematol, 94, 643 - 649

Load More